Physicians are more frequently encountering patients who are treated with deep brain stimulation (DBS), yet many MRI centers do not routinely perform MRI in this population. This warrants a safety assessment to improve DBS patients’ accessibility to MRI, thereby improving their care while simultaneously providing a new tool for neuromodulation research.
A phantom simulating a patient with a DBS neuromodulation device (DBS lead model 3387 and IPG Activa PC model 37601) was constructed and used. Temperature changes at the most ventral DBS electrode contacts, implantable pulse generator (IPG) voltages, specific absorption rate (SAR), and B1+rms were recorded during 3-T MRI scanning. Safety data were acquired with a transmit body multi-array receive and quadrature transmit-receive head coil during various pulse sequences, using numerous DBS configurations from “the worst” to “the most common.”
In addition, 3-T MRI scanning (T1 and fMRI) was performed on 41 patients with fully internalized and active DBS using a quadrature transmit-receive head coil. MR images, neurological examination findings, and stability of the IPG impedances were assessed.
In the phantom study, temperature rises at the DBS electrodes were less than 2°C for both coils during 3D SPGR, EPI, DTI, and SWI. Sequences with intense radiofrequency pulses such as T2-weighted sequences may cause higher heating (due to their higher SAR). The IPG did not power off and kept a constant firing rate, and its average voltage output was unchanged. The 41 DBS patients underwent 3-T MRI with no adverse event.
Under the experimental conditions used in this study, 3-T MRI scanning of DBS patients with selected pulse sequences appears to be safe. Generally, T2-weighted sequences (using routine protocols) should be avoided in DBS patients. Complementary 3-T MRI phantom safety data suggest that imaging conditions that are less restrictive than those used in the patients in this study, such as using transmit body multi-array receive coils, may also be safe. Given the interplay between the implanted DBS neuromodulation device and the MRI system, these findings are specific to the experimental conditions in this study.
ABBREVIATIONSASL = arterial spin labeling; B1+rms = root-mean-square value of the MRI effective component of the RF magnetic [B1] field; DBS = deep brain stimulation; DTI = diffusion tensor imaging; fMRI = functional magnetic resonance imaging; FSE = fast spin echo; GRE-EPI = gradient recalled echo–echo-planar imaging; IPG = implantable pulse generator; PD = Parkinson’s disease; RF = radiofrequency; SAR = specific absorption rate; SPGR = spoiled gradient recalled; SWI = susceptibility-weighted imaging.
Correspondence Andres M. Lozano: Toronto Western Hospital, Toronto, ON, Canada. email@example.com.
INCLUDE WHEN CITING Published online February 22, 2019; DOI: 10.3171/2018.11.JNS181338.
Disclosures Dr. Hancu reports being a GE Global Research employee. Dr. Lozano reports being the owner of Functional Neuromodulation and a consultant for Boston Scientific, Medtronic, Abbott, and St. Jude Medical.
BhidayasiriRBronsteinJMSinhaSKrahlSEAhnSBehnkeEJ: Bilateral neurostimulation systems used for deep brain stimulation: in vitro study of MRI-related heating at 1.5 T and implications for clinical imaging of the brain. Magn Reson Imaging23:549–5552005
GolestaniradLPilitsisJMartinALarsonPKeilBBonmassarG: Variation of RF heating around deep brain stimulation leads during 3.0 T MRI in fourteen patient-derived realistic lead models: the role of extracranial lead management in ISMRM 25th Annual Meeting and ExhibitionApril 22–27 2017 (https://www.ismrm.org/17/program_files/O87.htm) [Accessed December 16 2018]
GuerinPSeranoPIaconoMHerringtonTWidgeADoughertyD: Patient specific modeling of deep brain stimulation patients for MRI safety studies in ISMRM 25th Annual Meeting and ExhibitionApril 22–27 2017 (https://www.ismrm.org/17/program_files/PP21.htm) [Accessed December 16 2018]
HancuIFivelandERanjanMPrusikJDimarzioMRashiaT: On the (non-)equivalency of monopolar and bipolar settings for deep brain stimulation fMRI studies of Parkinson’s disease patients. J Magn Reson Imaging[epub ahead of print] 2018
Health Canada (CA): Guidelines on Exposure to Electromagnetic Fields From Magnetic Resonance Clinical Systems—Safety Code 26. Ottawa, ON: Health Canada2008(http://www.hc-sc.gc.ca/ewh-semt/pubs/radiation/87ehd-dhm127/index-eng.php) [Accessed December 16 2018]
PhillipsMDBakerKBLoweMJTkachJACooperSEKopellBH: Parkinson disease: pattern of functional MR imaging activation during deep brain stimulation of subthalamic nucleus—initial experience. Radiology239:209–2162006
RezaiARFinelliDNyenhuisJAHrdlickaGTkachJSharanA: Neurostimulation systems for deep brain stimulation: in vitro evaluation of magnetic resonance imaging-related heating at 1.5 tesla. J Magn Reson Imaging15:241–2502002
RezaiARLozanoAMCrawleyAPJoyMLDavisKDKwanCL: Thalamic stimulation and functional magnetic resonance imaging: localization of cortical and subcortical activation with implanted electrodes. Technical note. J Neurosurg90:583–5901999
RezaiARPhillipsMBakerKBSharanADNyenhuisJTkachJ: Neurostimulation system used for deep brain stimulation (DBS): MR safety issues and implications of failing to follow safety recommendations. Invest Radiol39:300–3032004
US Food & Drug Administration: Criteria for Significant Risk Investigations of Magnetic Resonance Diagnostic Devices—Guidance for Industry and Food and Drug Administration Staff. Silver Spring, MD: US Food & Drug Administration2015(https://www.fda.gov/RegulatoryInformation/Guidances/ucm072686.htm) [Accessed December 16 2017]